Ebanga
E468968
Ebanga is a monoclonal antibody drug used to treat Zaire ebolavirus infection (Ebola virus disease).
Statements (29)
| Predicate | Object |
|---|---|
| instanceOf |
antiviral drug
ⓘ
biologic medicinal product ⓘ monoclonal antibody ⓘ |
| administrationSetting | hospital or clinical setting ⓘ |
| approvalYear | 2020 ⓘ |
| ATCCode | J06BD ⓘ |
| belongsTo | Ebola virus disease treatments ⓘ |
| countryOfApproval | United States NERFINISHED ⓘ |
| developedFor | treatment of Ebola virus disease caused by Zaire ebolavirus ⓘ |
| dosageForm | solution for intravenous infusion ⓘ |
| drugClass | monoclonal antibodies against infectious agents ⓘ |
| hasGenericName | ansuvimab NERFINISHED ⓘ |
| indicatedFor | treatment of infection caused by Zaire ebolavirus (EBOV) ⓘ |
| indicatedPopulation | patients with laboratory-confirmed Zaire ebolavirus infection ⓘ |
| isHumanMonoclonalAntibody | true ⓘ |
| legalStatus | Rx-only in the United States ⓘ |
| mechanismOfAction | binds to Zaire ebolavirus glycoprotein and neutralizes the virus ⓘ |
| origin | human monoclonal antibody ⓘ |
| pharmacologicalEffect | virus neutralization ⓘ |
| prescriptionStatus | prescription only ⓘ |
| regulatoryAgencyApproval | U.S. Food and Drug Administration NERFINISHED ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| target | Zaire ebolavirus glycoprotein NERFINISHED ⓘ |
| therapeuticArea |
infectious diseases
ⓘ
virology ⓘ |
| therapyType | single monoclonal antibody therapy ⓘ |
| treats |
Ebola virus disease
ⓘ
Zaire ebolavirus infection ⓘ |
| usedIn | outbreaks of Ebola virus disease caused by Zaire ebolavirus ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.